The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
New facility ‘Amber Wing’ adds 55 beds and strengthens surgical, cardiac, robotic and preventive care infrastructure for women in Mumbai
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration
Subscribe To Our Newsletter & Stay Updated
